Revisiting the donor screening protocol of faecal microbiota transplantation (FMT): a systematic review-Reference-Cited by-同舟云学术

Revisiting the donor screening protocol of faecal microbiota transplantation (FMT): a systematic review

Published:2023-05-04 Issue: Volume: Page:gutjnl-2023-329515
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Ng Rita WY^ORCID,Dharmaratne Priyanga,Wong Sunny^ORCID,Hawkey Peter,Chan Paul,Ip Margaret

Funder

Seed fund from the Centre for gut microbiota research at the Faculty of Medicine, The Chinese University of Hong Kong

Publisher

BMJ

Subject

Gastroenterology

Reference10 articles.

1. Haifer C , Luu LDW , Paramsothy S , et al . Microbial determinants of effective donors in faecal microbiota transplantation for UC. Gut 2022:gutjnl-2022-327742. doi:10.1136/gutjnl-2022-327742

2. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic

3. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation – screening and testing of stool donors for multi-drug resistant organisms. Available: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation [Accessed 14 Feb 2023].

4. Rita WN , Dharmaratne P , Margaret I . An update of the contemporary donor screening tests used in fecal microbiota transplantation for its future developments: A systematic review. INPLASY 2021. doi:10.37766/inplasy2021.12.0063 Available: https://doi.org/10.37766/inplasy2021.12.0063

5. Faecal microbiota transplantation--the austrian approach;Kump;Clin Microbiol Infect,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Faecal microbiota transplantation associated adverse events;Current Issues in Pharmacy and Medical Sciences;2024-09-01

2. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines;Journal of Hospital Infection;2024-06

3. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines;Gut;2024-04-12

4. Microbiome and lung cancer: carcinogenic mechanisms, early cancer diagnosis, and promising microbial therapies;Critical Reviews in Oncology/Hematology;2024-04

5. Synthetic microbial consortia for the treatment of Clostridioides difficile infection in mice model;Microbial Biotechnology;2023-08-21